3B BlackBio Dx Share Price

3B Blackbio Dx Limited, with its corporate operations in Bhopal, functions as a molecular diagnostic solution provider in India. The company designs and manufactures diagnostic kits for infectious diseases, oncology, and human genetics. 3B Blackbio Dx also offers agrochemical products, reflecting its diversified business approach. The company’s reach extends to diagnostic laboratories and healthcare providers across the country. 3B Blackbio Dx share price on NSE and BSE indicates how market participants react to the company’s operational performance and developments in the diagnostic sector.

The company’s financial health depends on the adoption of its PCR kits, new product approvals, and its ability to serve the research and diagnostic markets. 3B Blackbio Dx stock price is influenced by factors such as earnings, the pace of new assay launches, and regulatory changes in the medical devices sector. In the longer run, strategies such as expanding the kit portfolio, entering new geographies, and increasing brand adoption among labs affect 3B Blackbio Dx stock price movements. These factors need to be monitored closely to understand the company’s valuation.

3B Blackbio Dx live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the 3B Blackbio Dx live price helps in observing short-term price volatility. It also shows how a stock moves relative to the broader healthcare index. Furthermore, monitoring 3B Blackbio Dx share price today helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

3B BlackBio Dx Fundamentals

1. Company Background

3B BlackBio Dx Limited is a molecular diagnostics company incorporated in 1993. The company is headquartered in Bhopal, Madhya Pradesh, India. It is engaged in the development, manufacturing, and commercialization of molecular diagnostic products, particularly real-time PCR (RT-PCR) kits used for the detection of infectious diseases, oncology markers, and genetic conditions. The company operates through its TRUPCR brand and has established capabilities in research and development, manufacturing, and quality-controlled production. Over time, it has expanded its product portfolio and strengthened its presence in domestic and international diagnostic markets, supplying to laboratories, hospitals, and research institutions.

2. Company Product Lines

• Molecular Diagnostic Kits (TRUPCR)
  • RT-PCR kits for infectious diseases, oncology, and genetic testing
• Reagents and Consumables
  • Supporting reagents and materials used in molecular testing workflows
• Extraction and Sample Preparation Kits
  • Products used for nucleic acid extraction and sample processing
• Quality Control and Validation Products
  • Controls and standards for diagnostic accuracy and testing validation

3. Company Revenue Model

• Sale of Diagnostic Kits
  • Revenue from supplying RT-PCR kits and related diagnostic products to laboratories and hospitals
• Sale of Reagents and Consumables
  • Recurring income from consumables used in testing processes
• Institutional and Export Sales
  • Revenue from government tenders, institutional buyers, and international markets
• Product Portfolio Expansion
  • Income driven by introduction of new diagnostic kits and testing solutions

4. Geographic Presence

• Headquarters
  • Bhopal, Madhya Pradesh, India
• Manufacturing and R&D Facilities
  • Centralized facilities in Bhopal supporting production and research activities
• Domestic Presence
  • Distribution network covering multiple regions across India
• International Presence
  • Exports to various countries through distributors and partners

5. Key Milestones

• 1993: Incorporation of the company
• 2010s: Development and expansion of molecular diagnostic product portfolio
• 2020: Launch and scale-up of RT-PCR kits for infectious disease testing, including COVID-19
• 2020s: Expansion into international markets and strengthening of R&D capabilities

6. Industry Perspective

The biotechnology and diagnostics outlook remains highly sensitive to domestic healthcare infrastructure and policy shifts. Emerging industry trends point towards increased modernization in pathology and molecular testing. Rising demand for accurate, rapid diagnostic tools supports capacity utilization across the sector.

Regulatory frameworks continue to evolve across the region to ensure medical compliance and quality control. Companies must adapt to these shifting policies to maintain relevance and secure government tenders.

Ultimately, macroeconomic variables affect the 3B BlackBio Dx stock price. Market conditions dictate broader investor appetite for healthcare equities.

3B Blackbio Dx Stock Market Presence: Listings & Index Representation

3B Blackbio Dx Limited is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). 3B Blackbio Dx share price is available for trading on the NSE under the symbol 3BBLACKBIO and on the BSE with the scrip code 532067. The company’s market presence is primarily within the small-cap segment of the market. Due to its size and sector focus, 3B Blackbio Dx stock price is generally tracked by investors interested in the diagnostics and biotechnology industry.

3B Blackbio Dx is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap diagnostics company in India. While it is not included in benchmark indices like the Sensex or Nifty, it is a constituent of wider market indices such as the BSE SmallCap index, which tracks a large universe of listed companies across sectors. In addition, the company is included in the BSE Healthcare index and broader composite indices like the BSE AllCap index, which captures companies across large, mid, and small-cap segments. 3B Blackbio Dx share price is also tracked within the BSE Commodities index due to its agrochemical legacy, providing a unique cross-sector presence. The inclusion of 3B Blackbio Dx stock price in these indices ensures visibility among institutional investors and funds that track these benchmarks for passive investment strategies.

3B Blackbio Dx Stock Performance and Share Price History

3B Blackbio Dx share price on NSE reflects its status as a molecular diagnostic kit manufacturer in India. Performance is driven by the company’s ability to develop new assays, the level of adoption by diagnostic labs, and the management of research and development costs. Investors compare 3B Blackbio Dx share price today with other diagnostic and life sciences companies to gauge relative performance within the small-cap healthcare space. These underlying factors are often visible through real market movements across different periods. Similar trends are observed during earnings-driven movements, particularly when the company reports quarterly sales of its PCR kits.

Broader sector strength, driven by demand for infectious disease testing and oncology screening, has also played a role in supporting 3B Blackbio Dx share price. In addition to operational and sector-led factors, corporate actions such as dividend announcements can also have a significant impact on 3B Blackbio Dx share price movements in the short term, even when a company’s fundamentals remain strong. The company paid a dividend in recent years, showing its ability to reward shareholders. This shows how corporate actions can trigger short-term swings, even within a regulated diagnostics framework influenced by government health policies and insurance coverage for tests.

While short-term movements reflect events and announcements, longer-term valuation trends are visible through 3B Blackbio Dx share price 52-week high and low, providing context beyond daily or weekly changes. Highs indicate strong demand for the company’s kits and stable margins, while lows align with market corrections or sector volatility. These levels capture the impacts of health policies, disease outbreak trends, and earnings visibility, providing context for the stock’s historical performance. 3B Blackbio Dx stock performance reflects the trading behaviour of a small-cap diagnostics company operating within India’s regulated medical devices sector. The company’s diversified product portfolio across infectious diseases, oncology, and human genetics has shaped its 3B Blackbio Dx share price history.

Over time, the stock has shown long-term wealth creation, marked by periods of sharp gains and phases of consolidation. Between 2020 and 2025, 3B Blackbio Dx stock price delivered significant returns. The company saw a sharp increase in value during the pandemic period due to demand for its PCR kits. From 2024 onwards, 3B Blackbio Dx share price has shown positive momentum, supported by strong core business performance. 3B Blackbio Dx stock performance over time has closely followed India’s healthcare demand and policy cycles. For instance, 3B Blackbio Dx share price reached a significant high, following increased testing demand for various diseases.

Over longer investment horizons, the stock has delivered meaningful returns. These returns highlight consistent growth aligned with expanding diagnostic access and increasing health awareness across the Indian economy. Despite post-pandemic corrections, 3B Blackbio Dx shares showed resilience. While the broader healthcare sector faced challenges with reduced testing volumes, the company’s focus on new product development and its agrochemical business helped the stock retain value. Prudent management and a strong brand reputation in the PCR kit market kept shares stable amid market volatility.

3B Blackbio Dx share price has seen decreases due to several recurring reasons. A slowdown in the sale of diagnostic kits or a drop in adoption by labs directly impacts profitability and leads to selling pressure. Changes in government policy, such as price caps on medical devices or the withdrawal of tax benefits for research, can also cause 3B Blackbio Dx stock price to fall. Furthermore, any increase in operational costs like raw material prices for chemicals or salaries for scientific staff, without a matching rise in kit sales, squeezes the company’s margins, making 3B Blackbio Dx share price less attractive. Periods of economic slowdown that affect discretionary health check-up spending raise concerns about testing volumes, leading to a drop in 3B Blackbio Dx share price.

3B Blackbio Dx stock price is also sensitive to regulatory changes in medical insurance; if insurance reimbursement rates for molecular tests are reduced, it can lead to a decrease in 3B Blackbio Dx stock price as investors adjust expectations for future revenue growth. Broader market sell-offs in small-cap stocks also pull 3B Blackbio Dx share price down, regardless of the company’s individual performance. A decrease in footfall at diagnostic labs or lower sales of non-COVID kits directly hurts the company’s revenue, resulting in a lower valuation for 3B Blackbio Dx share price. Historical data shows that 3B Blackbio Dx share price performance has seen periods of underperformance relative to the Nifty and Sensex during times of intense competition or when the company fails to launch new products as quickly as peers. Returns patterns indicate that the stock often experiences a calendar-year-end rally, but also deep corrections during the summer months based on the agrochemical business cycle.

3B Blackbio Dx Investor Relevance and Role in Portfolio

3B Blackbio Dx share price is a consideration for investors building small-cap and diagnostic sector portfolios, offering exposure to the molecular diagnostics and agrochemical industries. Inclusion in healthcare and small-cap indices underscores its importance in India’s diagnostic testing space. The company’s dual focus on life sciences and agrochemicals makes it a distinct consideration for long-term allocations aiming for diversification within the healthcare sector.

3B Blackbio Dx equity is held by a mix of domestic and international investors, reflecting its standing in India’s diagnostics sector. Prominent mutual fund holders include Motilal Oswal Mutual Fund and Bandhan Mutual Fund, which hold the stock through their healthcare ETFs. Other institutional investors include various insurance companies and small-cap focused funds. This broad investor base, with increasing institutional participation, underscores the company’s role as a holding in both domestic and global portfolios focused on diagnostic services and life sciences tools.

Beyond fundamentals and ownership, 3B Blackbio Dx stock is actively monitored in the cash market, where delivery percentage and volume patterns reflect expectations on kit sales and regulatory policy actions. The stock is available for trading on the NSE and BSE, allowing investors to take positions based on their outlook for the diagnostic sector. Market participants watch these delivery and volume indicators to gauge sentiment around quarterly results and policy announcements. Technical indicators such as 3B Blackbio Dx share price RSI, MACD, and MFI provide additional insight into short-term momentum shifts in the company’s stock price.

While these indicators are primarily used for near-term trading decisions, they also help investors understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short-term and weekly timeframe, 3B Blackbio Dx share price has exhibited relatively stable price movements compared to the broader small-cap market. This consistency suggests that, despite occasional fluctuations indicated by momentum indicators, the stock maintains a generally steady trading pattern.

3B Blackbio Dx beta has generally remained moderate, reflecting its position as a small-cap diagnostic stock with a diversified business model. Over shorter timeframes, such as the one-month period, 3B Blackbio Dx stock price has shown relatively higher sensitivity to market movements, indicating short-term volatility. During the three-month period, this sensitivity appears more balanced, suggesting a closer alignment with broader market trends. Across longer durations, such as the six-month and one-year periods, the beta trends lower, indicating reduced volatility and a weaker correlation with overall market fluctuations. This shift suggests that over time, the stock behaves more defensively, which is typical for companies in the diagnostic services sector. Overall, these variations across different timeframes highlight that while 3B Blackbio Dx price may experience short-term fluctuations, its longer-term volatility remains relatively stable, reinforcing its characteristics as a fundamentally steady diagnostic stock.

3B Blackbio Dx Sectoral Relevance and Peer Positioning

3B Blackbio Dx sector relevance stems from its scale in molecular diagnostic kit manufacturing, its portfolio of assays for infectious diseases and oncology, and its brand recognition in key markets. This establishes it as a key small-cap diagnostic provider supporting India’s medical testing ecosystem. Peer comparisons with companies such as Krsnaa Diagnostics, Metropolis Healthcare, Dr. Lal Pathlabs, Thyrocare, and other diagnostic chains focus on test volume growth, average realisation per test, and geographical reach rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of health insurance penetration, disease prevalence, and government health schemes further highlights 3B Blackbio Dx’s positioning within India’s broader diagnostic market.

3B Blackbio Dx market cap reflects its position as a small-sized participant in India’s diagnostic sector. Over the years, the company’s valuation has moved in phases tied to demand for its PCR kits. During periods of high testing demand, the market cap increased substantially. In quieter periods, it moderated as investors reassessed growth expectations from the core business. The company’s market cap remains sensitive to new product announcements and changes in government health policy. This history shows how investor perception of the company’s role in the diagnostic supply chain has evolved over different market cycles.

3B Blackbio Dx earnings history shows a clear link between diagnostic testing demand and company profitability. The company has reported total income growth in several recent years, supported by its core molecular diagnostic business. In certain quarters, earnings have seen a significant increase due to a surge in testing volumes. In other periods, earnings have stabilised as the business returned to normal demand patterns. The company’s agrochemical division also provides a steady earnings base, reducing reliance solely on the diagnostic segment. This history illustrates the company’s ability to generate income from its diversified operations.

3B Blackbio Dx EPS provides insight into its operational performance and income generation from kit sales and technical services. Between 2021 and 2023, earnings per share reflected strong profitability. In 2024, EPS stabilised as demand for testing normalised. In 2025, EPS increased, driven by continued strong sales of the company’s assay portfolio. More recent quarterly performance suggests that EPS has remained steady, indicating consistent ongoing earnings from the diagnostic operations. The EPS trajectory demonstrates the company’s ability to convert its scientific expertise into per-share earnings for its shareholders over time.

3B Blackbio Dx P/E ratio reflects how investors perceive the company’s earnings relative to its stable revenue streams from kit manufacturing. In earlier years, the ratio remained at relatively moderate levels, indicating steady but measured market expectations. During periods of high diagnostic demand, the valuation rose sharply as investors reassessed the company’s growth prospects. In more recent times, the ratio moderated and began to stabilise, reflecting a more balanced view of the company’s earnings potential. Overall, these changes highlight how market sentiment evolved alongside the company’s business cycle and the broader diagnostic industry trends.

Summary
3B Blackbio Dx operates as a molecular diagnostic kit manufacturer in India. The company serves diagnostic labs with tests for infectious diseases and oncology. 3B Blackbio Dx stock price reflects the demand for these testing solutions. 3B Blackbio Dx stock price also responds to the performance of its agrochemical business. The company maintains a focused portfolio and serves a niche market. Its performance is linked to health awareness and laboratory testing trends.